After a record year for IPOs put billions in the hands of drug developers and saw some of the industry’s mainstay venture capital firms debut their first post-downturn funds, it seems like halcyon days for biotech startups. But despite the warming climate, many are sticking to the hyper-efficient model that gained popularity when capital was far more scarce.

…read more

Source: Biotech boom or no, many startups are staying virtual


0 No comments